MV-130 by Inmunotek for Lower Respiratory Tract Infections: Likelihood of Approval

MV-130 is under clinical development by Inmunotek and currently in Phase II for Lower Respiratory Tract Infections.

Study reveals metabolic markers linked to long COVID-19 severity

Long COVID-19, or post-acute sequelae of SARS-CoV-2 infection (PASC), is a global health phenomenon characterized by persistent symptoms following the acute phase of COVID-19.

April 13, 2024

Opinion | ‘That’s a Society-Ending Pandemic’: What We Heard This Week

“That’s a society-ending pandemic.” — James Lawler, MD, MPH, of the University of Nebraska Medical Center’s Global Center for Health Security, on viruses with high

April 29, 2024

Raw milk can be safe — but it depends on something in short supply

When H5N1 avian flu was detected in commercial raw milk samples from a dairy called Raw Farm in California in December, the company released a

January 14, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.